Eli Lilly and Company has appointed Leena Gandhi, MD, PhD, a thoracic oncologist with expertise in immunotherapy and early drug development, to lead immuno-oncology medical development at Lilly Oncology, effective June 25, 2018.

Dr. Gandhi is currently the Director of Thoracic Medical Oncology and an associate professor of medicine at the New York University School of Medicine. After joining Lilly, she will lead a team of scientists that oversees the Lilly Oncology immunotherapy portfolio. She will report to Kimberly Blackwell, MD, Vice President of Early Phase Development and Immuno-oncology.

Source: Eli Lilly and Company